354 related articles for article (PubMed ID: 33200233)
21. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer.
Vedat Bayoglu I; Yildiz I; Varol U; Cokmert S; Kucukzeybek Y; Alacacioglu A; Demir L; Dirican A; Akyol M; Yildiz Y; Oktay Tarhan M
J BUON; 2015; 20(2):460-7. PubMed ID: 26011336
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
23. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Modest DP; Rivera F; Bachet JB; de Braud F; Pietrantonio F; Koukakis R; Demonty G; Douillard JY
Int J Cancer; 2019 Jul; 145(2):576-585. PubMed ID: 30614531
[TBL] [Abstract][Full Text] [Related]
24. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
25. Effects of Goshajinkigan (TJ-107) for oxaliplatin-induced peripheral neurotoxicity using the functional assessment of cancer therapy/gynecologic oncology group 12-item neurotoxicity questionnaire in a Phase II, multicenter, randomized, double-blind, placebo-controlled trial.
Aoyama T; Morita S; Kono T; Hata T; Mishima H; Sakamoto J
J Cancer Res Ther; 2021; 17(6):1473-1478. PubMed ID: 34916380
[TBL] [Abstract][Full Text] [Related]
26. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.
Stefansson M; Nygren P
Acta Oncol; 2016; 55(9-10):1227-1235. PubMed ID: 27550718
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802).
Ohta T; Kato T; Kawakami H; Miyake Y; Goto M; Iwamoto S; Otsuji T; Nakamura M; Sugimoto N; Okamura S; Kotaka M; Tsujie M; Tokunaga Y; Mishima H; Hata T; Shimokawa T; Kurokawa Y; Satoh T
Int J Clin Oncol; 2020 Jul; 25(7):1291-1298. PubMed ID: 32219630
[TBL] [Abstract][Full Text] [Related]
28. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
Van Cutsem E; Prenen H; D'Haens G; Bennouna J; Carrato A; Ducreux M; Bouché O; Sobrero A; Latini L; Staines H; Oum'Hamed Z; Dressler H; Studeny M; Capdevila J
Ann Oncol; 2015 Oct; 26(10):2085-91. PubMed ID: 26272806
[TBL] [Abstract][Full Text] [Related]
29. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR
Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810
[TBL] [Abstract][Full Text] [Related]
30. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.
Beijers AJ; Mols F; Vreugdenhil G
Support Care Cancer; 2014 Jul; 22(7):1999-2007. PubMed ID: 24728618
[TBL] [Abstract][Full Text] [Related]
31. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
Vincenzi B; Frezza AM; Schiavon G; Spoto C; Silvestris N; Addeo R; Catalano V; Graziano F; Santini D; Tonini G
Support Care Cancer; 2013 May; 21(5):1313-9. PubMed ID: 23196819
[TBL] [Abstract][Full Text] [Related]
32. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
35. Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
Tanishima H; Tominaga T; Kimura M; Maeda T; Shirai Y; Horiuchi T
Support Care Cancer; 2017 May; 25(5):1383-1389. PubMed ID: 27921224
[TBL] [Abstract][Full Text] [Related]
36. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.
Gui Q; Li D; Zhuge Y; Xu C
Asian Pac J Cancer Prev; 2021 Mar; 22(3):705-709. PubMed ID: 33773532
[TBL] [Abstract][Full Text] [Related]
38. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.
Overman MJ; Ferrarotto R; Raghav K; George B; Qiao W; Machado KK; Saltz LB; Mazard T; Vauthey JN; Hoff PM; Hobbs B; Loyer EM; Kopetz S
J Natl Cancer Inst; 2018 Aug; 110(8):888-894. PubMed ID: 29346573
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
[TBL] [Abstract][Full Text] [Related]
40. Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.
Inoue N; Ishida H; Sano M; Kishino T; Okada N; Kumamoto K; Ishibashi K
Int J Clin Oncol; 2012 Aug; 17(4):341-7. PubMed ID: 21833683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
